Latest news with #Connect
Yahoo
4 days ago
- General
- Yahoo
Security camera sign-ups rise in St. Johns County as officials address access concerns
St. Johns County Sheriff's Office saw a rise in people and businesses registering for its crime-fighting initiative, Connect St. Johns, a program that encourages the public to share access to their security cameras. However, according to the Sheriff's Office, a widespread misconception slows participation. Officials said the issue is the belief that law enforcement has unrestricted access to private cameras. >>> STREAM ACTION NEWS JAX LIVE <<< 'That's not what this is. What this is—you're simply telling us, I have cameras at my house, and if you need some help with a situation, please notify me and I'll let you know,' said St. Johns County Sheriff's Office Commander, George Harrigan. The initiative, launched in 2023, has two levels. The first level notifies the Sheriff's Office that a resident or business has cameras and allows them to be contacted for footage if needed. [DOWNLOAD: Free Action News Jax app for alerts as news breaks] The second level, called the 'Integrate' system, gives law enforcement direct access—but only if the participant chooses to grant it. This level is mainly used by businesses, organizations, and places of worship. 'So this initiative has been imperative in helping us solve crime. There've been several situations where it's been a huge help in successfully solving crime, saving lives, and resolving incidents,' Harrigan said. Participation in the program is entirely voluntary, and anyone can opt out at any time, said St. Johns County Sheriff's Office. 'And then you decide you don't want to do that, we certainly can remove your information,' Harrigan added. [SIGN UP: Action News Jax Daily Headlines Newsletter] As the community grows, more residents and businesses join the initiative. 'I think it's a great idea and matter of fact, we're already doing this with the Flagler Beach Police Department,' said Bonita Boutique owner, Dror Zanani. 'I think it's a good thing because everybody wants to be protected,' said local resident, Jeromey Altland. The Jacksonville Sheriff's Office launched a similar program, Connect Duval, in 2023. Currently, Connect St. Johns has 1,200 registered cameras, with nearly 1,000 fully integrated into the system. Click here to download the free Action News Jax news and weather apps, click here to download the Action News Jax Now app for your smart TV and click here to stream Action News Jax live.
Hans India
25-05-2025
- Hans India
Past not only about history, but gives ideas to deal with today's world: Odisha Guv
Odisha Governor Hari Babu Kambhampati on Sunday suggested that Odisha can strengthen its historical ties with Southeast Asian countries by enhancing port infrastructure, adopting green shipping, and promoting digital and cultural connectivity. During his address at the valedictory ceremony of the 3rd International Conference on Indian Cultural Heritage (ICICH) held in Bhubaneswar, Kambhamapati suggested that modern nations can learn new ideas from their glorious heritage. 'The past is not just about history, but gives us useful ideas for dealing with today's world,' said Kambhampati. The Governor also emphasised the enduring relevance of Odisha's maritime heritage in promoting connectivity, cultural exchange, and sustainable development. Speaking on the theme 'Kalinga and Southeast Asia: The Civilisation Connect,' Kambhampati stated that the legacy of ancient Kalinga's maritime endeavours offers important lessons for Southeast Asia in addressing environmental and developmental challenges. 'Odisha's rich history of maritime trade, exploration, and cultural exchange with countries like Indonesia, Malaysia, Myanmar, Thailand, Cambodia, and Vietnam is not just a matter of pride but a guide for contemporary regional cooperation,' he remarked. He praised the collaborative efforts of the Odia Language, Literature and Culture Department, Utkal University, and the Institute of Media Studies for organising the conference, calling it a meaningful step in reconnecting with Odisha's glorious past. The Governor noted that Kalinga, now Odisha, had strong maritime and cultural ties with Southeast Asia for over two thousand years. 'People from this region travelled widely, establishing links whose influence can still be seen today in architecture, inscriptions, customs, and place names,' he said. He emphasised that Kalinga's maritime network played a major role in the spread of Indian culture and religion. 'Temples like Angkor Wat in Cambodia and Borobudur in Indonesia show influences of Kalinga's temple architecture. The spread of the Ramayana, Mahabharata, and Sanskrit, and the celebration of festivals like Nyepi in Indonesia and Pchum Ben in Cambodia, reflect deep-rooted cultural bonds,' he said. These exchanges, he added, were based on mutual respect and enriched local traditions. He also stressed the need for joint research and heritage education to instil pride in future generations. Among others who addressed the occasion were Cuttack MP Bhartruhari Mahtab, former Foreign Secretary of India Lalit Mansingh, Principal Secretary of the Odia Language, Literature and Culture Department Sanjeeb Kumar Mishra, and Chairman of the One Asia Foundation, Patita Paban Mishra. The vote of thanks was delivered by Professor Upendra Padhi, Chairman of the 3rd ICICH.
Hans India
24-05-2025
- Business
- Hans India
TGCHE signs MoU with NASSOM's IT-ITeS Sector Skills Council
Hyderabad: Minister for IT, D Sridhar Babu emphasised the crucial role of the Government of Telangana in the growth and development of the Information Technology and Communications (IT&C) sector. During an event on Friday marking the signing of a Memorandum of Understanding (MoU) between the Telangana Council of Higher Education (TGCHE) and NASSCOM's IT-ITeS Sector Skills Council, he reiterated the Chief Minister's vision to empower every graduate with industry-relevant skills. He praised the collaborative efforts of TGCHE and NASSCOM in advancing this important mission. He highlighted the transformation of ITIs into Advanced Training Centres (ATCs), which will ensure job placement for all students. He further aimed to establish Hyderabad as the skilled capital of India. Additionally, he stressed the significance of industry-academia collaboration by focusing on imparting skills that meet market demand and providing suitable industry internships for students in Telangana. Dr Abhilasha Gaur, CEO of the IT-ITeS Sector Skills Council, NASSCOM, highlighted the substantial contributions made by NASSCOM for the development of the IT industry in India. She also outlined various initiatives by the IT-ITeS Sector Skills Council aimed at strengthening skill development across the sector. Prof V Balakista Reddy, Chairman of TGCHE, showcased recent initiatives to align higher education with industry demands. He elaborated on comprehensive curriculum reforms at the undergraduate level, ensuring that all students are exposed to technology-driven courses in emerging domains such as Digital Marketing, Cybersecurity, Fintech, Artificial Intelligence, and Sustainable Sciences. These transformative changes aim to significantly enhance the employability and industry readiness of graduates in Telangana. The collaboration will offer micro-learning content, foundation and deep-skilling courses (both free and paid), and a specialised offline course in 'Embedded Software Development and Testing' to build essential digital capabilities. NASSCOM will facilitate the upskilling of one lakh learners annually over the next three years in Telangana. TGCHE will encourage universities and colleges to develop internal talent pools by motivating students to complete certifications that align academic learning with industry demands. Completion certificates will be awarded to eligible learners upon successful course completion. Certified learners will be linked to potential employers via the Skill Sector Council (SSC) NASSCOM's Talent Connect- an employment-enabling platform- that supports their transition from learning to earning.
Yahoo
20-05-2025
- Automotive
- Yahoo
NET Trans offering on-demand EV ride services in Greeneville
GREENEVILLE, Tenn. (WJHL) — People in Greeneville and Tusculum can now request on-demand ride services from NET Trans's electric vehicles (EVs). NET Trans, a program at the First TN Human Resource Agency, announced on Tuesday that it had expanded to offer the same-day, on-demand EV rides through its new Connect service. 3 orphaned bear cubs rescued in Sullivan County People can access Connect by using the NET Trans mobile app. The service is open to everyone and can be used to schedule same-day trips. Ride services are available on a first-come, first-served basis and can be used within the Greeneville and Tusculum city limits. NET Trans's traditional services will continue to operate for trips outside of Greeneville. The NET Trans app can be downloaded through the Google Play Store and Apple App Store. Ride fares can be paid using cash, check, card or customer balance. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
20-05-2025
- Business
- Yahoo
Connect Biopharma Presents Data Supporting Development of Rademikibart at the American Thoracic Society (ATS) 2025 International Conference
– Rademikibart significantly improved airway function, as measured by FEV1, within a day and significantly reduced acute exacerbations in patients with inflammation-mediated chronic asthma strongly supporting ongoing Phase 2 acute exacerbation studies in asthma and COPD which are expected to report topline data in 1H26 – – New preclinical data highlights differentiated structural and molecular dynamics of rademikibart with enhanced interleukin-4 receptor alpha (IL-4Rα) inhibition compared to dupilumab providing a molecular basis for the differentiated efficacy and safety observed with rademikibart presented at this meeting – SAN DIEGO, May 20, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming acute and chronic care of asthma and chronic obstructive pulmonary disease (COPD), today announced clinical and preclinical data supporting rademikibart, the Company's next-generation, potentially best-in-class anti-interleukin-4-receptor alpha (IL-4Rα) antibody, which was presented at the American Thoracic Society (ATS) 2025 International Conference, taking place from May 18-21, 2025, in San Francisco. 'We are pleased to share new clinical and preclinical data highlighting rademikibart's potential as a best-in-class treatment for patients with asthma or COPD experiencing an acute exacerbation,' said Barry Quart, Pharm.D., CEO and Director of Connect Biopharma. 'The new analyses from our previously completed Phase 2b study not only demonstrate rademikibart's rapid onset of action and significant improvement in lung function, but also further differentiate its safety profile, overcoming limitations of existing IL-4Rα inhibitors on the market. Taken together, these data reinforce our confidence in our clinical development plan and provide strong commercial rationale for rademikibart as a potentially superior next-generation IL-4Rα inhibitor.' Title: Rapid Improvement in Lung Function Observed with Rademikibart in Patients with Moderate-to-Severe Uncontrolled Asthma At-home spirometry readings from Connect's Phase 2b trial of rademikibart for moderate-to-severe uncontrolled asthma were evaluated in a post-hoc analysis to assess rademikibart's ability to rapidly improve lung function. Rademikibart rapidly improved lung function (FEV1) during the initial week of treatment, and most FEV1 increase was observed within 24 hours. Improvements in self-assessed prebronchodilator FEV1 were greatest in patients with elevated eosinophil counts (≥300 cells/µL) with or without elevated exhaled nitric oxide (FeNO ≥25 ppb), markers of type 2 inflammation, as compared with the overall population. Patients with type 2 inflammatory asthma in this study also showed a significant reduction in acute exacerbations. Findings support rademikibart's potential as an effective therapy for patients with asthma or COPD experiencing an acute exacerbation, providing both fast-acting and sustained improvements in lung function. Title: Efficacy of Rademikibart in COPD-like Patients: Sub-analyses From the Phase 2b Trial in Patients with Moderate-to-Severe Asthma Results from the Company's Phase 2b trial of rademikibart in moderate-to-severe asthma were assessed in a post-hoc analysis to determine rademikibart's efficacy in subgroup of COPD-like patients, defined as asthma onset after 40 years of age and post−bronchodilator FEV1/FVC ratio <0.7. Rademikibart significantly improved prebronchodilator FEV1 from first assessment and was sustained through 24 weeks of treatment, with greatest improvements in patients with elevated baseline eosinophil counts (≥150 cells/µL and ≥300 cells/µL). These results suggest that rademikibart has the potential to improve outcomes for patients with COPD, particularly in patients with eosinophilic-driven COPD. Title: Effect of Rademikibart on Blood Eosinophil Counts in Patients with Asthma: Is There an IL-4Rα Class Effect? In a post-hoc analysis, eosinophil data from the Company's Phase 2b trial of rademikibart and from the Phase 3 VENTURE and QUEST trials of dupilumab were indirectly compared to determine whether hypereosinophilia is an IL-4Rα inhibitor class effect following published cases of dupilumab-associated hypereosinophilia. Rademikibart treatment groups were associated with substantially lower proportions of patients experiencing high post-baseline eosinophil counts than with dupilumab treatment groups. Proportions of patients with high post-baseline eosinophil counts were comparable in the placebo groups, indicating that differences in the active treatment groups are due to drug effect. In the rademikibart treatment groups mean eosinophil counts decreased by approximately 30% at Week 24, compared to a mean eosinophil increase between 50% and 120% for dupilumab during 52 weeks of treatment. Based on this analysis, the lack of an increase in eosinophils with rademikibart suggests that increased eosinophil counts observed in published data for dupilumab is unlikely to be an IL-4Rα inhibitor class effect, further differentiating rademikibart's safety profile as a potentially best-in-class IL-4Rα inhibitor. Title: Optimized Second-generation IL-4Rα Inhibition: Structural and Molecular Dynamics Properties of Rademikibart Fab-IL-4Rα Complex Rademikibart is an optimized next-generation human monoclonal antibody targeting IL-4Rα. In this study, Connect evaluated the atomic-resolution 3D structures of rademikibart and dupilumab, that may lead to an understanding of the differences in efficacy and safety between the two drugs. The x-ray crystal structure of rademikibart Fab-IL-4Rα complex revealed an ~60° rotation of rademikibart on IL-4Rα compared to dupilumab, optimizing interference with the natural IL-4/IL-13 epitope, while dupilumab binds to IL-4Rα through only domain 1, thereby incompletely engaging the natural IL-4/IL-13 epitope on IL-4Rα. Compared to dupilumab, molecular dynamics studies showed rademikibart forms a very strong and stable interaction with IL-4Rα, confirmed structurally by lower B-factors (less motion) and more hydrogen bonds (stronger binding) than dupilumab. These results further support previously published data showing that rademikibart demonstrated better inhibition of STAT6 intracellular signaling, provided similar potency in prohibiting both IL-4-induced TARC release and IL-4-induced B cell activation and has more than 2-fold higher binding affinity to IL-4Rα compared to dupilumab. These data support the underlying molecular and structural rationale for enhanced IL-4Rα inhibition by rademikibart compared to dupilumab. The poster presentations will be available on Connect's website under the Presentations and Publications section. About Connect Biopharma and RademikibartConnect Biopharma is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and COPD. Headquartered in San Diego, California, the company is advancing rademikibart, a next-generation, potentially best-in-class anti-interleukin-4-receptor alpha (IL-4Rα) antibody. With an initial focus on acute exacerbations—an area with significant unmet need—rademikibart has the potential to also drive chronic utilization in asthma and COPD amongst the approximately 1 million asthma patients and 1.3 million COPD patients in the U.S. who experience acute exacerbations annually. In a Phase 2 trial for asthma, rademikibart demonstrated strong efficacy and safety data, with clinically meaningful reductions in exacerbations and rapid, statistically significant improvements in forced expiratory volume in one second (FEV1), observed within one week—and in most cases, within 24 hours via home spirometry. For more information visit Forward-Looking Statements This press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995, as amended (the 'Act'). Forward-looking statements are statements that are not of historical fact and include, without limitation, statements regarding future events, our future financial condition, results of operations, business strategy and plans, prospective products (as well as their potential to achieve a differentiated, competitive, or favorable benefit or profile or trend, including on safety, tolerability, improvement, maintenance, clinical response, dosing, efficacy and/or convenience), planned or expected product approval applications or approvals, anticipated milestones, expected data readouts and enrollments, research and development plans and costs, potential future partnerships, expectations about existing partnerships, timing and likelihood of success, objectives of management for future operations, future results of anticipated product development efforts, and adequacy of existing cash and potential partnership funding to fund operations and capital expenditure requirements, as well as statements regarding industry trends. These statements are based on management's current expectations of future events only as of the date of this press release and are inherently subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control, including, among other things: the ability of our clinical trials to demonstrate safety and efficacy of our product candidates and other positive results; whether we will need expanded or additional trials in order to obtain regulatory approval for our product candidates; our ability to obtain and maintain regulatory approval of our product candidates; existing regulations and regulatory developments in the U.S., the PRC, Europe and other jurisdictions; the ability of our current cash and investments position to support planned operations; our plans and ability to obtain, maintain, protect and enforce our intellectual property rights and our proprietary technologies, including extensions of existing patent terms where available; our continued reliance on third parties to conduct additional clinical trials of our product candidates, and for the manufacture of our product candidates for preclinical studies and clinical trials; and the degree of market acceptance of our product candidates, if approved, by physicians, patients, healthcare payors and others in the medical community. Words such as 'aim,' 'anticipate,' 'believe,' 'could,' 'expect,' 'feel,' 'goal,' 'intend,' 'may,' 'optimistic,' 'plan,' 'potential,' 'promising,' 'will,' and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements necessarily contain these identifying words. The inclusion of forward-looking statements should not be regarded as a representation by Connect Biopharma that any of its expectations, projections or plans will be achieved. Actual results may differ materially due to the risks and uncertainties inherent in our business and other risks described in our filings with the U.S. Securities and Exchange Commission (the 'SEC'). Further information regarding these and other risks is included under the heading 'Risk Factors' in our annual and periodic reports filed with the SEC. These forward-looking statements should not be taken as forecasts or promises nor should they be taken as implying any indication, assurance or guarantee that the assumptions on which such forward-looking statements have been made are correct or exhaustive or, in the case of the assumptions, fully stated in this presentation. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You are cautioned not to place undue reliance on the scientific data presented or these forward-looking statements, which speak only as of the date of this presentation. Except as required by law, Connect Biopharma undertakes no obligation to publicly update any forward-looking statements, whether because of new information, future events or otherwise. Connect Biopharma claims the protection of the safe harbor for forward-looking statements contained in the Act for all forward-looking statements. This press release discusses our product candidate, rademikibart, which is under clinical investigation and has not yet been approved for marketing by the U.S. Food and Drug Administration or by any other regulatory agency. No representation is made as to the safety or effectiveness of rademikibart for the uses for which it is being studied. The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Investor Relations Contact: Alex Lobo Precision AQ 698-8802 Media Contact: Ignacio Guerrero-Ros, Ph.D., or David SchullRusso Partners, (858) 717-2310 or (646) 942-5604Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
